Replication Medical Inc.
This article was originally published in Start Up
Replication Medical is developing a spinal disc nucleus replacement based on a two phase, expandable hydrogel that has properties that ideally suit it for the intervertebral disc space. The implant swells and contracts to fill the disc space; it swells when a person is "downloaded" at night, and compresses water out when the spine is loaded.
You may also be interested in...
The vitality and dynamism in spine surpasses any other medical device segment. Although it's still early in the field, there's a clear first mover advantage, given the long development cycle of spine devices. The time to place bets is now.
Spine arthroplasty--replacing either the entire disc or simply the nucleus--is one of the most promising new therapies to treat patients with herniated discs and degenerative disc disease. But the technology has had a rocky history: rushed into patients too soon, without proper clinical trials, say critics, disc replacement languished in Europe and took a long time to attract interest in the US. Moreover, first generation arthroplasty products, most notably discs, had several drawbacks that limited adoption--some were very hard to implant, for example, while others were too stiff and tended to extrude. Companies like Disc Dynamics hope to ride the wave of interest in disc and nucleus replacement as it develops new technology that is both superior to first generation products and backed by the proper kinds of clinical studies.
With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.